felodipine has been researched along with Coronary Heart Disease in 22 studies
Felodipine: A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels.
felodipine : The mixed (methyl, ethyl) diester of 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium-channel blocker, it lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. It is used in the management of hypertension and angina pectoris.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the negative inotropic effects of the four dihydropyridine-calcium-channel-blockers nifedipine (NIF), isradipine (ISR), nisoldipine (NIS) and felodipine (FEL) in man, the drugs were infused within 30 min intravenously in an equihypotensive dosage (NIF 2 mg, ISR 0." | 6.67 | [Comparison of the cardiodepressive effects of nifedipine, isradipine, nisoldipine and felodipine in patients with coronary heart disease]. ( Ickrath, O; Karsch, KR; Mauser, M; Voelker, W, 1993) |
| "The effects of felodipine on haemodynamics and exercise capacity have been studied in patients with angina pectoris." | 5.06 | Felodipine in ischaemic heart disease. ( Sheridan, DJ; Sheridan, JV; Thomas, P, 1987) |
| "The calcium antagonist felodipine, the lipid-peroxidation inhibitor H290/51, and the angiotensin II type 1 (AT1)-receptor antagonist candesartan all exert beneficial effects on myocardial ischemia/reperfusion injury." | 3.70 | Combination of a calcium antagonist, a lipid-peroxidation inhibitor, and an angiotensin AT1-receptor antagonist provides additive myocardial infarct size-limiting effect in pigs. ( Rydén, L; Shimizu, M; Sjöquist, PO; Wang, QD, 1999) |
| "The systemic and coronary haemodynamic effects of felodipine were evaluated at rest and during stress induced atrial pacing in fourteen patients with chronic cardiac failure, secondary to coronary heart disease." | 3.67 | Felodipine in ventricular dysfunction. ( Hutton, I; Tweddel, AC, 1986) |
| "To compare the negative inotropic effects of the four dihydropyridine-calcium-channel-blockers nifedipine (NIF), isradipine (ISR), nisoldipine (NIS) and felodipine (FEL) in man, the drugs were infused within 30 min intravenously in an equihypotensive dosage (NIF 2 mg, ISR 0." | 2.67 | [Comparison of the cardiodepressive effects of nifedipine, isradipine, nisoldipine and felodipine in patients with coronary heart disease]. ( Ickrath, O; Karsch, KR; Mauser, M; Voelker, W, 1993) |
| "In 30 consecutive patients with Prinzmetal's angina pectoris, the antiischemic effect of felodipine, a new long-acting vasoselective calcium antagonist, administered at doses of 10 and 20 mg once daily was compared with that of the well-established therapeutic regimen with nifedipine administered at a dose of 20 mg 4 times daily." | 2.67 | Felodipine (once daily) versus nifedipine (four times daily) for Prinzmetal's angina pectoris. ( Ardissino, D; Barberis, P; Mussini, A; Rolla, A; Sardina, M; Savonitto, S; Specchia, G; Zanini, P, 1991) |
| "In conclusion, in patients with chronic cardiac failure, treatment with a calcium channel blocker produced sustained haemodynamic improvement, particularly on exercise, and combination with nitrate produced further benefit." | 2.66 | Calcium channel blocker and isosorbide 5-mononitrate in the management of chronic cardiac failure. ( Hutton, I; Martin, W; McGhie, AI; Tweddel, AC, 1987) |
| "Felodipine is a highly vascular selective calcium entry blocker, with a vascular selectivity ratio greater than 100, as shown experimentally." | 2.39 | Vascular selective calcium entry blockers in the treatment of cardiovascular disorders: focus on felodipine. ( Cheng, CP; Elvelin, L; Little, WC; Nordlander, M, 1995) |
| "Felodipine was equally effective as nifedipine in preventing an alpha 2-adrenoceptor-mediated increase in coronary resistance and the resulting contractile dysfunction distal to severe coronary stenoses." | 2.38 | Prevention of alpha-adrenergic coronary constriction by calcium-antagonists. ( Deussen, A; Guth, BD; Heusch, G, 1990) |
| "Felodipine is a novel dihydropyridine calcium-channel antagonist with vascular selectivity." | 1.28 | Felodipine prevents the poststenotic myocardial ischemia induced by alpha 2-adrenergic coronary constriction. ( Ehring, T; Heusch, G, 1990) |
| " Thus at the dosage used felodipine was a potent dilator of systemic arterioles but had no direct effect on left ventricular function." | 1.27 | Acute haemodynamic effects of felodipine during beta blockade in patients with coronary artery disease. ( Culling, W; Ruttley, MS; Sheridan, DJ, 1984) |
| "Felodipine is a dihydropyridine calcium antagonist that has a positive inotropic effect at low concentration in the dog in vivo." | 1.27 | Problem of measuring the positive inotropic property of a vasodilating drug: an illustration using felodipine. ( Drake-Holland, AJ; Mills, C; Noble, MI; Pugh, S, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (36.36) | 18.7374 |
| 1990's | 13 (59.09) | 18.2507 |
| 2000's | 1 (4.55) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gokce, N | 1 |
| Holbrook, M | 1 |
| Hunter, LM | 1 |
| Palmisano, J | 1 |
| Vigalok, E | 1 |
| Keaney, JF | 1 |
| Vita, JA | 1 |
| Culling, W | 2 |
| Ruttley, MS | 1 |
| Sheridan, DJ | 3 |
| Mauser, M | 1 |
| Voelker, W | 1 |
| Ickrath, O | 1 |
| Karsch, KR | 1 |
| Little, WC | 1 |
| Cheng, CP | 1 |
| Elvelin, L | 1 |
| Nordlander, M | 1 |
| Vergroesen, I | 1 |
| Kal, JE | 1 |
| Spaan, JA | 1 |
| Van Wezel, HB | 1 |
| Rodríguez Moreno, C | 1 |
| Shimizu, M | 1 |
| Wang, QD | 1 |
| Sjöquist, PO | 1 |
| Rydén, L | 1 |
| Amlie, JP | 1 |
| Endresen, K | 1 |
| Sire, S | 1 |
| Gradman, AH | 1 |
| Ardissino, D | 2 |
| Savonitto, S | 2 |
| Mussini, A | 1 |
| Zanini, P | 2 |
| Rolla, A | 2 |
| Barberis, P | 2 |
| Sardina, M | 1 |
| Specchia, G | 2 |
| Heusch, G | 2 |
| Deussen, A | 1 |
| Guth, BD | 1 |
| Ehring, T | 1 |
| Strauer, BE | 1 |
| De Servi, S | 1 |
| Dunselman, PH | 1 |
| van der Mark, TW | 1 |
| Kuntze, CE | 1 |
| van Bruggen, A | 1 |
| Hamer, JP | 1 |
| Scaf, AH | 1 |
| Wesseling, H | 1 |
| Lie, KI | 1 |
| Sheridan, JV | 1 |
| Thomas, P | 1 |
| Drake-Holland, AJ | 1 |
| Pugh, S | 1 |
| Noble, MI | 1 |
| Mills, C | 1 |
| Hutton, I | 2 |
| McGhie, AI | 1 |
| Martin, W | 1 |
| Tweddel, AC | 2 |
| Emanuelsson, H | 1 |
| Holmberg, S | 1 |
| Curtis, MJ | 1 |
| Johnston, KM | 1 |
| Macleod, BA | 1 |
| Walker, MJ | 1 |
2 reviews available for felodipine and Coronary Heart Disease
| Article | Year |
|---|---|
Vascular selective calcium entry blockers in the treatment of cardiovascular disorders: focus on felodipine.
Topics: Amlodipine; Calcium Channel Blockers; Coronary Disease; Felodipine; Heart Failure; Hemodynamics; Hum | 1995 |
Prevention of alpha-adrenergic coronary constriction by calcium-antagonists.
Topics: Animals; Calcium Channel Blockers; Constriction, Pathologic; Coronary Circulation; Coronary Disease; | 1990 |
8 trials available for felodipine and Coronary Heart Disease
| Article | Year |
|---|---|
Acute effects of vasoactive drug treatment on brachial artery reactivity.
Topics: Adult; Analysis of Variance; Brachial Artery; Cardiovascular Agents; Coronary Disease; Double-Blind | 2002 |
[Comparison of the cardiodepressive effects of nifedipine, isradipine, nisoldipine and felodipine in patients with coronary heart disease].
Topics: Adult; Aged; Calcium Channel Blockers; Coronary Disease; Electrocardiography; Exercise Test; Felodip | 1993 |
Myocardial oxygen supply:demand ratio as reference for coronary vasodilatory drug effects in humans.
Topics: Aged; Cardiac Catheterization; Cardiac Pacing, Artificial; Coronary Artery Bypass; Coronary Circulat | 1997 |
Felodipine (once daily) versus nifedipine (four times daily) for Prinzmetal's angina pectoris.
Topics: Angina Pectoris, Variant; Coronary Angiography; Coronary Disease; Double-Blind Method; Electrocardio | 1991 |
Ability of calcium-entry blockade by felodipine to disclose different pathogenetic mechanisms behind hyperventilation-induced myocardial ischemia in men.
Topics: Coronary Angiography; Coronary Disease; Coronary Vessels; Double-Blind Method; Electrocardiography; | 1990 |
Different results in cardiopulmonary exercise tests after long-term treatment with felodipine and enalapril in patients with congestive heart failure due to ischaemic heart disease.
Topics: Aged; Coronary Disease; Double-Blind Method; Drug Evaluation; Enalapril; Exercise Test; Felodipine; | 1990 |
Felodipine in ischaemic heart disease.
Topics: Adult; Aged; Angina Pectoris; Antihypertensive Agents; Clinical Trials as Topic; Coronary Disease; D | 1987 |
Calcium channel blocker and isosorbide 5-mononitrate in the management of chronic cardiac failure.
Topics: Chronic Disease; Coronary Disease; Drug Therapy, Combination; Exercise Test; Felodipine; Heart Failu | 1987 |
12 other studies available for felodipine and Coronary Heart Disease
| Article | Year |
|---|---|
Acute haemodynamic effects of felodipine during beta blockade in patients with coronary artery disease.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiac Catheterization; Cardiac Pacing, A | 1984 |
[Calcium antagonists and their impact on coronary risk].
Topics: Anti-Arrhythmia Agents; Antihypertensive Agents; Calcium Channel Blockers; Clinical Trials as Topic; | 1998 |
Combination of a calcium antagonist, a lipid-peroxidation inhibitor, and an angiotensin AT1-receptor antagonist provides additive myocardial infarct size-limiting effect in pigs.
Topics: Anesthesia; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Antioxidants; Benzim | 1999 |
The effect of felodipine on the sinus and atrioventricular nodes in patients with ischemic heart disease.
Topics: Atrioventricular Node; Coronary Disease; Electrophysiology; Felodipine; Heart Conduction System; Hea | 1990 |
Hemodynamic effects of the vascular selective calcium antagonist felodipine in patients with impaired left ventricular function.
Topics: Coronary Disease; Felodipine; Heart Failure; Hemodynamics; Humans; Hypertension; Myocardial Contract | 1992 |
Felodipine prevents the poststenotic myocardial ischemia induced by alpha 2-adrenergic coronary constriction.
Topics: Adrenergic alpha-Agonists; Animals; Azepines; Constriction, Pathologic; Coronary Disease; Dogs; Felo | 1990 |
Significance of coronary circulation in hypertensive heart disease for development and prevention of heart failure.
Topics: Adult; Animals; Cardiac Output, Low; Cardiomegaly; Coronary Circulation; Coronary Disease; Coronary | 1990 |
Problem of measuring the positive inotropic property of a vasodilating drug: an illustration using felodipine.
Topics: Adult; Aged; Cardiotonic Agents; Coronary Disease; Felodipine; Female; Heart Function Tests; Hemodyn | 1987 |
Felodipine in ventricular dysfunction.
Topics: Adult; Cardiac Pacing, Artificial; Coronary Circulation; Coronary Disease; Exercise Test; Felodipine | 1986 |
Acute haemodynamic effects of felodipine in patients with coronary artery disease.
Topics: Antihypertensive Agents; Cardiac Catheterization; Coronary Disease; Felodipine; Heart Rate; Hemodyna | 1985 |
No adverse effects from high doses of felodipine to patients with coronary heart disease.
Topics: Coronary Circulation; Coronary Disease; Felodipine; Hemodynamics; Humans; Lactates; Lactic Acid; Mal | 1985 |
The actions of felodipine on arrhythmias and other responses to myocardial ischaemia in conscious rats.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Coronary Disease; Electrocard | 1985 |